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Concordancea b s t r a c t
Background: Two electrochemiluminescence (ECL) assays were developed which, together, can simulta-
neously measure serum antibodies against pneumococcal capsular polysaccharides (PnPS) for 17 sero-
types. The assays were validated for the 13 PnPS included in the 13-valent pneumococcal conjugate
vaccine (PCV13). As recommended by the World Health Organization (WHO), we compared the ECL
assays with the WHO reference enzyme-linked immunosorbent assay (ELISA) and derived a threshold
corresponding to the 0.35 mg/mL threshold established for the WHO reference ELISA for the non-
inferiority comparison and licensure of new PCVs against invasive pneumococcal disease.
Methods: A panel of 452 serum samples from children vaccinated with one of the three licensed PCVs was
assessed with the ECL assays and the WHO reference ELISA. The ECL assay threshold for the aggregated
seven PnPS included in the 7-valent PCV (PCV7) and serotype-specific thresholds were determined using
a receiver operating characteristics (ROC) curve-based approach and Deming regression. To evaluate con-
cordance between the ECL assays and the WHO reference ELISA, serostatus agreement rates between
both assays and geometric means of the ratios (GMRs) of concentrations obtained with both assays were
calculated.
Results: The thresholds for the seven aggregated PCV7 serotypes obtained with the ROC curve-based
approach and Deming regression approximated 0.35 mg/mL (0.38 and 0.34 mg/mL, respectively).
Individual thresholds for the PCV13 serotypes ranged between 0.24 and 0.51 mg/mL across both
approaches. Serostatus agreement rates using a 0.35 mg/mL threshold for both assays were 86.9% for
all PCV13 serotypes. GMRs ranged between 0.85 and 1.25 for 11/13 serotypes and were <1.29 for the
two remaining serotypes.
Conclusion: The ECL assays were comparable to the WHO reference ELISA and offer a sensitive, time- and
serum volume-saving method to quantify serotype-specific anti-PnPS antibodies in pediatric sera. A
0.35 mg/mL threshold will be used for each PCV13 serotype to assess PCV immunogenicity in clinical
trials.
 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the
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Streptococcus pneumoniae causes invasive infections, such as
meningitis and sepsis, and is also a major bacterial cause of muco-
sal infections, including otitis media and pneumonia. At least 97
different pneumococcal serotypes are known to circulate, but only
a small proportion is responsible for the majority of invasive infec-
tions [1]. These serotypes differ in the chemical composition and
antigenicity of their polysaccharide capsule, the bacteria’s most
important virulence factor [1].
Pneumococcal conjugate vaccines (PCVs), in which pneumococ-
cal capsular polysaccharides (PnPS) are covalently linked to carrier
proteins, have had a major impact on the burden of pneumococcal
disease [2,3]. A 7-valent PCV (PCV7, Pfizer Inc.) including PnPS of
seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) was licensed
based on efficacy results from several clinical trials [4–6]. PCV7
has meanwhile been replaced by two higher-valent PCVs: the
pneumococcal non-typeable Haemophilus influenzae protein D con-
jugate vaccine (PHiD-CV, GSK), containing PnPS of serotypes 1, 5,
and 7F in addition to the PCV7 PnPS, and the 13-valent PCV
(PCV13, Pfizer Inc.), containing PnPS of three more serotypes (3,
6A, and 19A) [2].
To accelerate access to the new PCVs, PHiD-CV and PCV13 were
licensed based on randomized trials comparing their immuno-
genicity with that of PCV7 [7–9]. The primary endpoint in such
studies was based on serotype-specific anti-PnPS immunoglobulin
G (IgG) antibody concentrations measured by enzyme-linked
immunosorbent assay (ELISA) approximately 1 month after the
primary vaccination series. Indeed, to license new PCVs for immu-
nization against invasive pneumococcal disease (IPD), the World
Health Organization (WHO) recommended that the immunogenic-
ity of the new vaccine is directly compared for non-inferiority with
that of PCV7 to bridge the efficacy of PCV7 against IPD to the new
vaccine [10,11]. Based on pooled efficacy and serology results
aggregated for the seven PCV7 serotypes obtained from three IPD
efficacy studies with PCV7 and a 9-valent PCV (PCV9, not licensed),
a threshold IgG antibody concentration of 0.35 mg/mL measured by
ELISA was recommended as a benchmark when comparing anti-
body responses between PCVs [10–12]. To standardize the mea-
surement of serum anti-PnPS IgG antibody concentrations, the
WHO established a reference ELISA, which included a 22F PnPS
pre-absorption step to increase specificity and for which the
0.35 mg/mL threshold was retained [11,12]. The WHO recommends
that any laboratory-specific modifications to the WHO reference
ELISA or any alternative assays developed to measure serotype-
specific anti-PnPS IgG antibody concentrations are adequately
bridged to the WHO reference assay to maintain the link between
immune responses to vaccination and the demonstration of pro-
tective efficacy of PCV7 against IPD. If alternative assay-specific
thresholds are proposed, robust justification of threshold equiva-
lence is needed [11], as was done for instance for GSK’s 22F-
inhibition ELISA [13,14].
Infant immunization studies often involve co-administration of
PCVs with combination vaccines, thus more than 30 different
assays per infant may need to be performed to determine the
immune response to all antigens in the administered vaccines. In
addition, new PCVs including more than 13 PnPS are being devel-
oped, further increasing the number of antigens to be assessed in
the limited amount of serum that can be collected from an infant.
Therefore, assays that are less time consuming, less labor-
intensive, and less serum volume demanding than the currently
used ELISAs are needed. A variety of alternative assays have been
developed to overcome the limitations of ELISA, including multi-
plexed bead assays and chemiluminescence-based solid phase
assays [15–20]. GSK has developed two complementary multiplex
electrochemiluminescence (ECL) assays based on the Meso ScaleDiscovery (MSD) technology, allowing simultaneous measurement
of antibodies to multiple PnPS using small volumes of serum
(<10 mL for all serologies). In these assays, serotype-specific serum
IgG antibodies bound to PnPS on the surface of multispot micro-
plates are detected using anti-human IgG secondary antibodies
with an electrochemiluminescent tag. In the presence of electrical
stimulation this tag emits light at an intensity that increases with
the amount of bound anti-PnPS IgG antibodies and hence with the
concentration present in the serum sample [21,22]. The newly
developed ECL assays combine 17 PnPS (9 in the first assay and 8
in the second) and were qualified and validated for the 13 PnPS
contained in PCV13, in line with guidelines developed by the Inter-
national Conference on Harmonization and the Center for Drug
Evaluation and Research [23,24]. The aim of the current study
was to compare the ECL assays performed at GSK (Rixensart, Bel-
gium) with the WHO reference ELISA performed at the Institute
of Child Health (ICH; London, United Kingdom), one of the two
WHO reference laboratories for pneumococcal serology. We
derived a threshold based on the seven PnPS included in PCV7 cor-
responding to the 0.35 mg/mL WHO reference ELISA threshold and
performed a bridging between the assays on the 13 PnPS included
in PCV13.2. Materials and methods
2.1. PnPS
Lyophilized PnPS for each PCV13 serotype to coat the micro-
plates for the ECL assays and for the WHO reference ELISA were
obtained from the American Type Culture Collection (Manassas,
VA, USA). Each PnPS was reconstituted at GSK (for the ECL assays)
or ICH (for the WHO reference ELISA) according to suppliers’
instructions at a final concentration of 1 mg/mL and kept frozen
at 20 C or 80 C until used.2.2. Standard serum and controls
The human pneumococcal standard reference serum, 007sp
(National Institute for Biological Standards and Control, Potters
Bar, Hertfordshire, UK), which has assigned anti-PnPS antibody
concentrations for the PCV13 serotypes [25,26], was used to gener-
ate a standard curve to determine antibody concentrations in the
ECL assays and WHO reference ELISA. Lyophilized serum was
reconstituted at GSK or ICH.
For the ECL assays, an IgG-depleted negative control serum
(Valley Biomedical, Winchester, VA, USA) containing no detectable
anti-PnPS antibodies as measured by the multiplex ECL assays and
two positive controls containing known levels of anti-PnPS (Gam-
magard S/D, Baxter, Lessines, Belgium; Biomnis, France Dom-
Tom) were also used.2.3. Panel of sera used for assay comparisons
The analyses to determine the ECL assay threshold and the
bridging analyses were performed on data generated from a panel
of sera collected from infants and children vaccinated with PCV7,
PHiD-CV, or PCV13 in 11 clinical trials previously performed by
GSK, predominantly in Europe. All trials had been conducted in
accordance with Good Clinical Practice guidelines and included
informed consent. Samples were selected based on volume avail-
ability and on anti-PnPS IgG concentrations that allowed coverage
of a broad analytical range. Within this panel, 452 serum samples
were analyzed for antibodies against PCV7 PnPS, of which 191
samples were also tested for antibodies against serotypes 1, 5,
2210 M. Feyssaguet et al. / Vaccine 37 (2019) 2208–2215and 7F PnPS, of which 53 samples were also tested for antibodies
against serotypes 3, 6A, and 19A PnPS.
2.4. ECL assay method
The two multiplex ECL assays developed by GSK are based on
the MSD technology, which uses an electrochemiluminescent
ruthenium tris(bipyridine)-labeled anti-human IgG antibody to
detect serum IgG antibodies bound to specific PnPS immobilized
on multispot microplates [21,22]. PnPS of serotypes 3, 4, 6B, 9V,
14, 18C, 19F, and 23F (ECL1) and 1, 5, 6A, 7F, and 19A (ECL2) were
immobilized at MSD (Rockville, MD, USA) by passive adsorption in
spots on the high-binding carbon electrode surface on the bottom
of each well of 96-well multispot microplates (10 spots per well).
Coated microplates were stored at 2–8 C until use and were
shown to be stable for more than 1 year at this temperature.
Samples were diluted at appropriate dilutions (1:1000 for test
serum, positive and negative control samples or 1:10,000 in case
of high concentrations; serial dilutions to obtain 11 standard
points for the 007sp reference serum) in Dulbecco’s phosphate buf-
fered saline (DPBS; pH 7.4), containing 0.05% Tween-20, 1% bovine
serum albumin (BSA), and 20 mg/mL pneumococcal cell wall
polysaccharide multi (CWPSmulti; Statens Serum Institute, Copen-
hagen, Denmark) and incubated overnight (16–24 h) at 2–8 C to
allow pre-absorption of the samples with CWPS multi. No pre-
absorption with 22F PnPS was done. Microplate wells were blocked
with 150 mL DPBS containing 5% BSA for 1 h at room temperature
on an orbital shaker. Wells were washed three times with 300 mL
DPBS (pH 7.4) containing 0.05% Tween-20 (DPBST). 30 mL of the
diluted and pre-absorbed samples were added to the blocked
pre-coated wells and plates were incubated for 1 h at room tem-
perature on an orbital shaker. Wells were washed three times with
300 mL DPBST and incubated with 30 mL ruthenium tris
(bipyridine)-labeled goat anti-human IgG antibody working solu-
tion (antibody: Southern Biotech, Birmingham, AL, USA; label:
MSD, Rockville, MD, USA; conjugated at GSK) for 1 h at room tem-
perature on an orbital shaker. After another three 300 mL washing
steps with DPBST, 150 mL ECL read buffer containing tripropy-
lamine (MSD, Rockville, MD, USA) was added in each well and
plates were read as soon as possible (within 1 h) after adding the
read buffer. Reading was done with an ECL plate reader, which
applies an electrical current across the carbon electrodes at the
bottom of the wells. In the presence of tripropylamine, this triggers
a redox reaction of the ruthenium tris(bipyridine) tag and the gen-
eration of a luminescent signal [21]. The signal was read at 620 nm
with a high-resolution cooled camera detector with no cross-talk
between spots (MSD SECTOR Imager 6000 or Imager S600).
Samples were tested at a single dilution in duplicate wells on
each plate, except for the 11 reference serum standard points,
which were tested in single wells on each plate. The mean ECL val-
ues of the duplicate samples were converted to concentrations in
mg/mL by interpolation on the reference standard curve which
was fit using a weighted four-parameter logistic regression model.
2.5. WHO reference ELISA method
The WHO reference ELISA was performed at ICH as previously
described [27]. In brief, 96-well microtiter plates were coated with
PnPS for the 13 PCV13 serotypes. Sera were pre-absorbed for
30 min at room temperature with 10 mg/mL CWPS and 5 mg/mL
serotype 22F PnPS. PnPS-coated plates were incubated with the
diluted pre-absorbed samples, washed, and incubated with alka-
line phosphatase-labeled goat anti-human secondary antibody.
Substrate (p-nitrophenyl phosphate) was added to induce a colori-
metric reaction. The optical density of each well was measured at
405 nm and 690 nm using an ELISA plate reader and comparedwith the reference standard to determine the concentration in
mg/mL using a weighted standardized curve-fitting four-
parameter logistic regression model.
The lower limits of quantitation (LLOQs) for the WHO reference
ELISA were <0.150 mg/mL for all serotypes and the upper limits of
quantitation (ULOQs) have not been defined. Inter-assay precision
for the WHO reference ELISA is summarized in Supplementary
table 1.
2.6. Statistical analyses
All statistical analyses were performed using SAS version 9.2,
9.3 or 9.4, depending on the analysis (SAS Institute Inc., Cary, NC,
USA). The ROC curves were drawn in R version 3.3.1 with the pROC
package.
Methods used to determine the performance characteristics of
the ECL assays are described in the Supplementary methods.
2.7. Determination of a threshold for the ECL assays
Two statistical methods were used to determine the ECL assays’
threshold corresponding to the previously established ELISA
threshold of 0.35 mg/mL: a receiver operating characteristics
(ROC) curve-based approach and Deming regressions.
As a primary analysis, the ROC curve-based approach was used
to derive the threshold for the aggregated seven PCV7 serotypes
based on data generated from the panel of samples from PCV7/
PHiD-CV/PCV13-vaccinated infants and children. The ROC analysis
was also used to derive thresholds for the aggregated 10 PHiD-CV
serotypes, the aggregated 13 PCV13 serotypes, and the thresholds
for each individual PCV13 serotype. A ROC curve plots the propor-
tion of true positives (sensitivity) versus the proportion of false
positives (1 – specificity) at various threshold levels (Fig. 1). Logis-
tic regressions were used to model the probability of the samples
to have a concentration <0.35 mg/mL or 0.35 mg/mL in the WHO
reference ELISA based on their log10 concentrations in the ECL
assays. The predicted probabilities were then used to calculate sen-
sitivities and specificities according to different cut-off values in
the ECL assays, which allowed drawing the ROC curves. The ROC
curves were used to choose the optimal thresholds based on our
tolerance for false positives (<0.35 mg/mL predicted to be
0.35 mg/mL in theWHO ELISA) and on our target for true positives
(0.35 mg/mL predicted to be 0.35 mg/mL in the WHO ELISA), i.e.,
looking for equal sensitivities and specificities.
Deming regressions [28] were performed as supportive analy-
ses. These account for the continuous characteristic and the mea-
surement error of concentrations from both assays. An error
variance ratio of 1 was assumed along the range of concentrations.
The analysis was performed on paired values between the assays’
LLOQs and ULOQs (the latter applicable to the ECL assays only).
Confidence intervals (CIs) for the ROC curve-based approach
and for Deming regressions were determined by bootstrapping.
To compare the different aggregate thresholds (0.35 mg/mL and
those obtained with the ROC curve-based approach and Deming
regression for the aggregated PCV7 serotypes), we looked at how
the different thresholds affected the contingency tables between
the ECL assays and the WHO reference ELISA in terms of the
serostatus of the samples for the aggregated PCV7 serotypes. We
calculated agreement rates between the ECL assays and the WHO
reference ELISA in terms of serostatus of the samples by dividing
the number of concordant paired samples (i.e., samples with con-
centrations either above the thresholds with both assays or below
the threshold with both assays) by the total number of tested valid
paired samples. For each threshold, we also calculated the differ-
ence between the proportion of samples that were positive in the
WHO ELISA and the proportion of samples that were positive in
Fig. 1. ROC curves from logistic model predictions of WHO ELISA status based on
ECL assay concentrations for aggregated and individual PCV7 serotypes. ROC,
receiver operating characteristics; WHO, World Health Organization; ELISA,
enzyme-linked immunosorbent assay; ECL, electrochemiluminescence; PCV7, 7-
valent pneumococcal conjugate vaccine; Agg7, aggregated seven PCV7 serotypes;
PS, polysaccharide. The X axis displays the specificity from the highest value (on the
left) to the smallest value (on the right). Threshold values corresponding to
observations of the curves closest to the upper left corner are the most performant.
95% bootstrapped confidence intervals of sensitivities and specificities allow
spotting the performances of the optimal cut-points identified by minimizing the
absolute values of the differences between sensitivities and specificities.
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assessing the symmetry of the discordants since the proportion
of samples that are positive in both assays is used in the calculation
of both proportions.2.8. Technical bridging: qualitative and quantitative concordance
We assessed both qualitative and quantitative concordance
between the ECL assays and the WHO reference ELISA. The analysis
was based on the final ECL assay threshold aggregated for the
seven PCV7 serotypes and the 0.35 mg/mL threshold for the WHO
reference ELISA.
For the qualitative concordance assessment, agreement rates
(overall, positive, and negative) between the assays were esti-
mated for each PCV13 serotype in terms of serostatus of the sam-
ples by dividing the number of concordant paired samples by the
total number of tested valid paired samples (overall agreement)
or by dividing the number of concordant paired samples above/be-
low both thresholds by the total number of tested valid paired
samples above/below the ELISA threshold (positive/negative agree-
ment). McNemar p-values were calculated to assess the imbalance
in the distribution of discordant samples. The acceptance criteria
for the qualitative part of the technical bridge were an overall
agreement at the final aggregate threshold for the ECL assays of
80% for all 13 PCV13 serotypes and of 90% for at least 66% of
the 13 serotypes.
For the quantitative concordance assessment, we calculated the
geometric means of individual ratios (GMR; ECL assay divided by
WHO reference ELISA) of pairs of concentration values falling
above the respective LLOQs in both assays and below the ULOQs
in the ECL assays. The GMR analysis was supported by the slopeof the Deming regression line and the Deming plot of the bias pre-
senting the individual ratios (ECL assay concentration over WHO
reference ELISA concentration) over the analytical range. The
acceptance criteria for the quantitative part of the technical bridge
were GMRs between 0.67 and 1.50 for all 13 serotypes and
between 0.80 and 1.25 for at least 66% of the 13 serotypes.3. Results
3.1. Performance characteristics of the ECL assays
The main performance characteristics of the ECL assays, as
established during the qualification and validation processes, are
summarized in Supplementary tables 2–4. The LLOQs by PnPS ran-
ged between 0.061 and 0.199 mg/mL; the ULOQs between 7.344
and 184.000 mg/mL (Supplementary table 2). Precision and linear-
ity were demonstrated between the LLOQs and ULOQs (Supple-
mentary table 3). Acceptance criteria for inter-assay precision
(i.e., coefficient of variation  30%) were met for all 13 PCV13 PnPS
(Supplementary table 3). Linearity was demonstrated for all 13
PnPS, i.e., 75% of the deviations from linearity fell between the
acceptance limits of 0.80–1.25 (Supplementary table 3). Accuracy,
assessed on the WHO quality control panel of 12 serum samples
from vaccinated adults [25,29], was acceptable: for nine
serotype-specific PnPS, antibody concentrations measured with
the ECL assays fell within ±40% of their assigned concentrations
using the WHO reference ELISA for at least 9 out of 12 tested sam-
ples (Supplementary table 4).3.2. Determination of a threshold for the ECL assays
Using the ROC curve-based approach (Fig. 1), the aggregate
threshold for the seven PCV7 serotypes was 0.38 mg/mL (95% CI:
0.366–0.402) (Table 1). The aggregate thresholds for the PHiD-CV
and PCV13 serotypes were 0.38 mg/mL (95% CIs: 0.366–0.399 and
0.367–0.401, respectively). No individual thresholds could be
derived for serotypes 3, 6A, and 19A because of too low numbers
of samples with antibody concentrations <0.35 mg/mL in the
WHO reference ELISA. Individual thresholds for the other serotypes
ranged between 0.24 mg/mL (for serotype 6B) and 0.51 mg/mL (for
serotype 4) (Table 1).
Using Deming regression, the estimated aggregate threshold for
the seven PCV7 serotypes was 0.34 mg/mL (95% CI: 0.330–0.348)
(Table 1, Fig. 2). Aggregate thresholds for the PHiD-CV and PCV13
serotypes were 0.34 mg/mL (95% CIs: 0.332–0.348 and 0.333–
0.348, respectively). Estimated thresholds for the individual
PCV13 serotypes ranged between 0.25 mg/mL (for serotypes 6B
and 19F) and 0.45 mg/mL (for serotype 5) (Table 1). No individual
threshold was derived for serotype 19A due to a lack of observa-
tions in the threshold area.
Given the wide analytical range of the ECL assays (Supplemen-
tary table 2), the aggregate threshold values for the ECL assays
obtained with the ROC curve-based method and Deming regres-
sion were very close to and on either side of the 0.35 mg/mL IPD
licensure threshold established for the WHO reference ELISA. To
evaluate whether an anti-PnPS concentration of 0.35 mg/mL could
be used as the aggregate threshold for the ECL assays, we evaluated
how the three different thresholds (0.38 mg/mL, 0.34 mg/mL, and
0.35 mg/mL) impacted the contingency tables between the ECL
assays and the WHO reference ELISA in terms of the serostatus of
the samples for the aggregated PCV7 serotypes (Supplementary
table 5). Agreement rates between the assays were 91.2% when
using 0.38 mg/mL as ECL threshold and 91.4% when using 0.34 or
0.35 mg/mL as ECL thresholds. The difference between the propor-
tion of samples that were positive in the WHO ELISA and the pro-
Table 1
Estimated ECL assay thresholds for aggregated and individual serotypes obtained through the ROC curve-based method and through Deming regression.
Serotype ROC curve-based method Deming regression
N ECL assay threshold,
mg/mL (95% CI)
Specificity, % (95% CI) Sensitivity, % (95% CI) N ECL assay threshold,
mg/mL (95% CI)
Aggregated PCV7 serotypes 3149 0.38 (0.366; 0.402) 91.22 (89.49; 92.96) 91.24 (90.04; 92.44) 2629 0.34 (0.330; 0.348)
Aggregated PHiD-CV serotypes 3718 0.38 (0.366; 0.399) 91.20 (89.59; 92.74) 91.17 (90.04; 92.30) 3078 0.34 (0.332; 0.348)
Aggregated PCV13 serotypes 3877 0.38 (0.367; 0.401) 91.33 (89.73; 92.86) 91.37 (90.27; 92.44) 3235 0.34 (0.333; 0.348)
1 190 0.34 (0.292; 0.401) 95.15 (92.23; 99.03) 95.40 (90.80; 98.85) 139 0.31 (0.292; 0.327)
3 53 NA NA NA 52 0.27 (0.219; 0.320)
4 451 0.51 (0.459; 0.557) 95.11 (91.85; 97.83) 95.13 (91.76; 97.38) 379 0.40 (0.378; 0.418)
5 188 0.45 (0.407; 0.506) 87.91 (80.22; 94.51) 87.63 (80.41; 93.81) 152 0.45 (0.428; 0.472)
6A 53 NA NA NA 52 0.34 (0.231; 0.483)
6B 451 0.24 (0.226; 0.273) 90.85 (85.92; 95.07) 90.61 (87.38; 93.85) 371 0.25 (0.237; 0.266)
7F 191 0.29 (0.243; 0.343) 90.77 (83.08; 96.92) 91.27 (85.71; 96.03) 158 0.28 (0.259; 0.301)
9V 452 0.50 (0.431; 0.566) 92.90 (88.76; 96.45) 92.58 (89.05; 95.05) 381 0.42 (0.387; 0.455)
14 451 0.36 (0.338; 0.450) 96.15 (90.38; 100.00) 96.24 (94.24; 97.99) 407 0.30 (0.276; 0.321)
18C 449 0.50 (0.462; 0.593) 94.33 (90.72; 97.42) 94.51 (91.76; 97.25) 351 0.42 (0.402; 0.447)
19A 53 NA NA NA 53 NA
19F 445 0.35 (0.260; 0.409) 88.46 (78.85; 96.15) 88.55 (84.99; 91.35) 395 0.25 (0.222; 0.275)
23F 450 0.32 (0.306; 0.340) 94.65 (91.44; 97.86) 94.68 (91.63; 97.34) 345 0.31 (0.298; 0.329)
ECL, electrochemiluminescence; ROC, receiver operating characteristics; N, number of valid paired results from the ECL assays and World Health Organization reference
enzyme-linked immunosorbent assay (ELISA) – for Deming regression, only values between the respective lower and upper limits of quantitation were used; CI, confidence
interval; PCV7, 7-valent pneumococcal conjugate vaccine; PHiD-CV, non-typeable Haemophilus influenzae protein D conjugate vaccine; PCV13, 13-valent pneumococcal
conjugate vaccine; NA, not applicable: could not be calculated because too few values were <0.35 mg/mL in the WHO reference ELISA (three for serotype 3, four for serotype
6A, none for serotype 19A), or, for Deming regression, due to a lack of observations in the threshold area (for 19A). Thresholds were calculated at three decimals and rounded
here to two decimals.
2212 M. Feyssaguet et al. / Vaccine 37 (2019) 2208–2215portion of samples that were positive in the ECL assays was 3.24%
when using 0.38 mg/mL as ECL threshold, 0.60% when using
0.34 mg/mL as ECL threshold and 1.11% when using 0.35 mg/mL as
ECL threshold. We therefore considered a concentration of
0.35 mg/mL as the final threshold for the ECL assays.
3.3. Technical bridge between the ECL assays and the WHO reference
ELISA
The qualitative concordance analyses were performed using a
threshold of 0.35 mg/mL for both the ECL assays and the WHO ref-
erence ELISA. The overall serostatus agreement rates between theFig. 2. Deming regression plotting ECL assay anti-PnPS concentrations in function
of WHO reference ELISA anti-PnPS concentrations for the aggregated PCV7
serotypes. ECL, electrochemiluminescence; PnPS, pneumococcal capsular polysac-
charide; WHO, World Health Organization; ELISA; enzyme-linked immunosorbent
assay; PCV7, 7-valent pneumococcal conjugate vaccine; N, number of valid paired
results from the ECL assays and WHO reference ELISA between the respective lower
and upper limits of quantitation; PI, prediction interval.ECL assays and the WHO reference ELISA ranged between 86.9%
(serotype 6B) and 100% (serotype 19A) and were 90% for 10 out
of 13 (77%) PCV13 serotypes. Therefore, both acceptance criteria
for the agreement between assays were met (80% for 100% of
PCV13 serotypes and 90% for 66% of PCV13 serotypes) (Table 2).
McNemar p-values showed statistically significant evidence of an
imbalance in the distribution of discordant samples for all sero-
types except 1, 3, and 6A: for serotypes 4, 5, 9V, and 18C, more
samples tested positive (0.35 mg/mL) with the ECL assay and neg-
ative with the WHO reference ELISA than vice versa; for serotypes
6B, 7F, 14, 19F, and 23F, the opposite was observed (Table 2).
The GMRs calculated from pairs of concentration values
obtained with the ECL assays and WHO reference ELISA falling
between the LLOQs and ULOQs ranged between 0.85 (serotype
6B) and 1.29 (serotype 9 V) for all PCV13 serotypes and were below
1.25 for 11 serotypes (85%) (Table 3). Therefore, both acceptance
criteria for the quantitative part of the bridge (GMRs 0.67–1.50
for 100% of serotypes and 0.80–1.25 for 66% of serotypes) were
met. Results from the Deming regression analysis supported this
outcome: the slopes and their 95% CIs ranged between 0.67 and
1.50 for 100% of serotypes and between 0.80 and 1.25 for 12
(92%, i.e., 66%) serotypes. Intercepts and slopes are shown in
Table 3 and the corresponding Deming regression plots and Dem-
ing plots of the bias in Supplementary Fig. 1.4. Discussion
Since the early 1980s, levels of IgG antibodies to PnPS in human
serum samples have been quantified using serotype-specific ELISAs
[30]. An international reference ELISA was established and, based
on a correlation between antibody levels and protective efficacy
of PCV7 against IPD, an anti-PnPS antibody concentration of
0.35 mg/mL has been used as a benchmark for non-inferiority when
assessing new PCVs in clinical trials [10–12]. Given the importance
of maintaining a link between PCV efficacy and serum IgG antibody
concentrations measured in a particular assay, the WHO issued
recommendations on the bridging of any new assay for anti-PnPS
antibody quantification to the reference ELISA and on the
establishment of assay-specific thresholds equivalent to the
Table 2
Qualitative concordance between the ECL assays and the WHO reference ELISA using the 0.35 mg/mL threshold in both assays.










1 190 82 99 5 4 95.3 94.3 96.1 1.0000
3 53 47 3 3 0 94.3 94.0 100.0 0.2500
4 451 264 151 3 33 92.0 98.9 82.1 <0.0001
5 188 94 70 3 21 87.2 96.9 76.9 0.0003
6A 53 47 4 2 0 96.2 95.9 100.0 0.5000
6B 451 254 138 55 4 86.9 82.2 97.2 <0.0001
7F 191 109 63 17 2 90.1 86.5 96.9 0.0007
9V 452 273 137 10 32 90.7 96.5 81.1 0.0009
14 451 386 48 13 4 96.2 96.7 92.3 0.0490
18C 449 250 158 5 36 90.9 98.0 81.4 <0.0001
19A 53 53 0 0 0 100.0 100.0 NA NA
19F 445 347 46 46 6 88.3 88.3 88.5 <0.0001
23F 450 242 184 21 3 94.7 92.0 98.4 0.0003
ECL, electrochemiluminescence; WHO, World Health Organization; ELISA, enzyme-linked immunosorbent assay; N, number of valid paired results from the ECL assays and
WHO reference ELISA; n, number of concordant or discordant pairs; NA, not applicable. Bold p-values indicate statistical significance (p < 0.05).
Table 3
Quantitative concordance between the ECL assays and the WHO reference ELISA.
Serotype N GMR (95% CI) Deming regression
Intercept (95% CI) Slope (95% CI)
1 139 0.95 (0.90; 1.00) 0.013 (0.033; 0.008) 1.091 (1.056; 1.127)
3 52 0.90 (0.82; 0.97) 0.054 (0.092; 0.017) 1.113 (1.005; 1.233)
4 379 1.24 (1.19; 1.28) 0.091 (0.076; 0.107) 1.079 (1.051; 1.108)
5 152 1.27 (1.21; 1.33) 0.090 (0.060; 0.121) 0.959 (0.890; 1.032)
6A 52 1.22 (1.03; 1.44) 0.059 (0.026; 0.145) 1.153 (0.968; 1.379)
6B 371 0.85 (0.82; 0.89) 0.078 (0.096; 0.060) 1.144 (1.113; 1.177)
7F 158 0.91 (0.87; 0.95) 0.048 (0.067; 0.029) 1.106 (1.073; 1.140)
9V 381 1.29 (1.23; 1.36) 0.114 (0.090; 0.137) 1.073 (1.027; 1.122)
14 407 0.89 (0.86; 0.92) 0.060 (0.081; 0.039) 1.021 (0.993; 1.050)
18C 351 1.19 (1.14; 1.24) 0.077 (0.059; 0.095) 0.987 (0.955; 1.020)
19A 53 1.24 (1.13; 1.36) 0.177 (0.114; 0.240) 0.897 (0.835; 0.963)
19F 395 0.91 (0.86; 0.96) 0.091 (0.122; 0.061) 1.129 (1.081; 1.178)
23F 345 0.93 (0.89; 0.96) 0.033 (0.050; 0.016) 1.034 (1.003; 1.065)
ECL, electrochemiluminescence; WHO, World Health Organization; ELISA, enzyme-linked immunosorbent assay; N, number of valid paired results from the ECL assays and
WHO reference ELISA between the respective lower and upper limits of quantitation; GMR, geometric mean of the individual ratios (ECL assay concentration over WHO
reference ELISA concentration); CI, confidence interval.
M. Feyssaguet et al. / Vaccine 37 (2019) 2208–2215 22130.35 mg/mL reference ELISA threshold [11]. Following this recom-
mendation, GSK established a 22F-inhibition ELISA with a thresh-
old of 0.2 mg/ml which was shown to correspond to a
concentration of 0.35 mg/mL measured with the WHO ELISA with-
out 22F pre-absorption [13,14] and was used during the clinical
development of PHiD-CV [31].
Similarly, in the current study, we compared the newly devel-
oped, qualified, and validated multiplex pneumococcal ECL assays
performed at GSK with the WHO reference ELISA performed at the
ICH [27]. The two approaches we used (ROC-curve based method
and Deming regression) both gave aggregated thresholds for the
seven PCV7 serotypes close to 0.35 mg/mL (0.38 mg/mL and
0.34 mg/mL, respectively), with no relevant differences in serosta-
tus agreement rates between assays when these three different
thresholds were used. We therefore chose the 0.35 mg/mL thresh-
old for subsequent concordance analyses between the ECL assays
and the WHO reference ELISA and showed that antibody concen-
trations obtained with both assays were highly comparable. The
predefined success criteria for serostatus agreement and for the
geometric mean of individual ratios of antibody concentrations
measured with the two assays were met. We did not observe a sys-
tematic trend for higher (or lower) anti-PnPS concentrations across
serotypes when using the ECL assays compared to the WHO refer-
ence ELISA. For some serotypes, concentrations were lower while
for others they were higher but GMRs were between 0.85 and1.29 for the 13 PCV13 serotypes. In line with these results, during
assay qualification, no systematic trend for lower or higher concen-
trations across serotypes was observed when comparing the anti-
PnPS concentrations obtained with the ECL assays for the WHO
quality control panel with their published concentrations using
the WHO reference ELISA. A high concordance between the assays
was also observed using the WHO quality control panel, with
GMRs ranging between 0.70 and 1.25 across the PCV13 serotypes.
Others recently developed a multiplex ECL assay (also based on
the MSD technology) to detect antibodies against the 15 PnPS
included in a new investigational 15-valent PCV (containing PnPS
for serotypes 22F and 33F in addition to the 13 PCV13 serotypes)
[32]. Based on the thresholds (aggregated over the 15 PnPS)
obtained from two different methods, a single ECL threshold value
of 0.35 mg/mL for each of the 15 serotypes was recommended to
assess serotype-specific antibody responses [32]. As such, these
results are similar to the results we obtained with our ECL assays.
The originally established ELISA threshold of 0.35 mg/mL used
for licensure of new PCVs against IPD was based on anti-PnPS
IgG antibody concentrations and efficacy estimates aggregated
for the seven PCV7 serotypes using pooled data from three IPD effi-
cacy trials in infants vaccinated with PCV7 or PCV9 [10,12].
Because IPD rates are low, serotype-specific vaccine efficacy esti-
mates from these trials were either not available or had too wide
CIs to allow estimation of a protective antibody concentration by
2214 M. Feyssaguet et al. / Vaccine 37 (2019) 2208–2215serotype. Moreover, the licensure of PCV7 was based on the aggre-
gated efficacy for the seven serotypes rather than serotype-specific
efficacy. It was therefore deemed acceptable to estimate a single
threshold applicable to all serotypes, using the simplifying
assumption that the concentration of antibodies needed to confer
protection was similar for all serotypes [10,12]. In line with this
approach, we calculated a single threshold aggregated for the
seven PCV7 serotypes for our ECL assays as our primary analysis.
We also calculated individual thresholds for each of the 13
PCV13 serotypes which did not deviate more than 1.5-fold from
the final 0.35 mg/mL ECL assay threshold for any of the serotypes.
Serotype-specific ELISA thresholds have been published for the
majority of PCV13 serotypes [33]. These range quite widely around
the 0.35 mg/mL aggregate threshold but have not yet been incorpo-
rated into accepted guidelines for licensing. This emphasizes the
importance of the 0.35 mg/mL aggregate threshold for the foresee-
able future.
The original 0.35 mg/mL threshold concentration was estimated
from reverse cumulative distribution curves (RCDCs) of antibody
concentrations in vaccinated children as the concentration corre-
sponding to the efficacy estimate [10,12]. RCDCs have also been
used to derive the concentration equivalent to the 0.35 mg/mL
WHO reference ELISA threshold for new assays or assay conditions
[13,14,32]. In the current study, we used two different methods: an
ROC curve-based approach and Deming regression. A draw-back of
the RCDC approach is that it does not take into account that the
same samples are tested in the new assay and the reference ELISA
(i.e., matching of pairs). By contrast, the two methods we used to
derive a threshold for the ECL assays do account for this. An advan-
tage of using Deming regression rather than the ROC curve-based
approach is that the former considers the continuous characteristic
of the concentrations obtained with the WHO reference ELISA and
takes into account measurement errors of both assays. We there-
fore consider Deming regression a good alternative method for
estimating assay thresholds.
Multiplex ECL assays have several advantages over ELISA. The
high speed of plate reading (<1 min per plate) and simultaneous
measurement of antibodies to multiple PnPS—in contrast to ELISA
which requires separate assays for each individual serotype—allow
for an increased throughput and the use of lower sample volumes
[15–19]. This is especially beneficial in infant vaccination studies
with PCVs (currently containing up to 13 different PnPS) and co-
administration of other vaccines, adding another 10 or more anti-
gens to be tested in limited serum volumes. Our multiplex ECL
assays allow addition of other PnPS and is therefore compatible
with future generation PCVs containing more than 13 PnPS.
The ECL assay has a wider dynamic range than ELISA, meaning
that low and high concentrations of antibodies can be measured
with a single sample dilution, therefore minimizing sample retest-
ing. A wider dynamic range has also been seen for Luminex-based
multiplexed microsphere assays developed by several laboratories
[15,16,19]. An advantage of the ECL assay compared to Luminex-
based multiplex assays is that—similar to ELISA—direct binding
of the PnPS to the surface of the ECL assay microplates through
passive adsorption minimizes impact on antigenicity. This con-
trasts with the Luminex-based multiplex assays which require
covalent binding of the PnPS to microspheres. Some of the methods
(and chemical modifications) used for conjugation of the PnPS to
the beads were shown to interfere with antigenicity of the PnPS,
while with other conjugation methods serotype-specific epitopes
appeared to remain intact [15,16,19,20].
In summary, the newly developed multiplex ECL assays which
were validated for the 13 PCV13 PnPS offer a highly sensitive,
robust, time- and serum volume-saving method for the detection
and quantification of serotype-specific anti-PnPS antibodies in
serum from infants and children. A concentration of 0.35 mg/mLwill be used as a threshold for each PCV13 serotype in future
assessments of PCV immunogenicity in clinical trials.Funding
This work was supported by GlaxoSmithKline Biologicals SA,
who was involved in all stages of the analyses and paid for all costs
associated with the development and publishing of this
manuscript.Disclosures
D Goldblatt’s, P De Gorguette D’Argoeuves’, and T Jones’ institu-
tion received a grant from the GSK group of companies for the con-
duct of this study, as well as grants from the GSK group of
companies, Sanofi Pasteur, and Merck for the conduct of other
studies. DG received personal remuneration from the GSK group
of companies, Sanofi Pasteur, and Merck for participating in advi-
sory boards. A Bellanger, A El Moussaoui, D Friel, E Merck, V Ver-
lant, F Nozay, M Feyssaguet, M Malevé, S Lallemand, and S
Schoonbroodt are employees of the GSK group of companies. DF,
EM, VV, FN, and SS hold shares in the GSK group of companies as
part of their employee remuneration. VV has pending patents in
the pneumococcal vaccine field.Author contributions
AB, DG, EM, FN, MF, SS and VV were involved in the design of
the study. AEM, DF, MF, PDGDA, SL, and TJ performed the study
and participated in the generation of the data. All authors partici-
pated in the analysis and interpretation of the data. All authors
reviewed and commented critically on drafts of the manuscript
for important intellectual content and gave final approval to sub-
mit for publication. All authors attest they meet the ICMJE criteria
for authorship. The corresponding author had final responsibility
to submit for publication. Drafts were developed by a professional
publication writer according to the recommendations, documenta-
tion, and outline provided by the lead author.Declaration of interests
The authors declare that they have no known competing finan-
cial interestsAcknowledgements
The authors would like to thank: Angélique Baclin, Dorota
Borys, Pierre Cambron, Nathalie De Schrevel, Francis Dessy, Max-
ime Durbecq, Sophie Germain, Philippe Hessens, Michael Kalai,
Patricia Lommel, Ariane Mathys, Fabrice Moreau, Pascal Philippart,
Isabelle Radoux and Magali Traskine for their participation and
help provided during the development of this study. The authors
would also like to thank Natalie Denef (XPE Pharma & Science c/
o GSK) for medical writing support and Olivier Box (XPE Pharma
& Science c/o GSK) for manuscript coordination and editorial
support.Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.vaccine.2019.03.011.
M. Feyssaguet et al. / Vaccine 37 (2019) 2208–2215 2215References
[1] Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al.
Pneumococcal capsules and their types: past, present, and future. Clin
Microbiol Rev 2015;28:871–99. https://doi.org/10.1128/cmr.00024-15.
[2] Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L,
et al. Pneumococcal Conjugate Vaccine (PCV) Product Assessment; 2017.
<https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-
assessment-april-25-2017.pdf> [accessed 16 August 2018].
[3] World Health Organization. Pneumococcal vaccines WHO position paper -
2012. Wkly Epidemiol Rec 2012;87:129–44.
[4] Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. safety and
immunogenicity of heptavalent pneumococcal conjugate vaccine in children.
Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr
Infect Dis J 2000;19:187–95.
[5] Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al.
Effectiveness of heptavalent pneumococcal conjugate vaccine in children
younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J
2002;21:810–5. https://doi.org/10.1097/01.inf.0000027926.99356.4c.
[6] Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a
pneumococcal conjugate vaccine against acute otitis media. N Engl J Med
2001;344:403–9. https://doi.org/10.1056/nejm200102083440602.
[7] Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al.
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed
7vCRM vaccine. Pediatr Infect Dis J 2009;28:S66–76. https://doi.org/10.1097/
INF.0b013e318199f8ef.
[8] Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. PCV13 Infant Study Group.
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Pediatrics 2010;125:866–75. https://doi.org/10.1542/peds.2009-1405.
[9] Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al.
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in
infants and toddlers. Pediatrics 2010;126:e493–505. https://doi.org/10.1542/
peds.2009-3027.
[10] Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, et al. Serological
criteria for evaluation and licensure of new pneumococcal conjugate vaccine
formulations for use in infants. Vaccine 2003;21:3265–72. https://doi.org/
10.1016/S0264-410X(03)00230-5.
[11] World Health Organization Expert Committee on Biological Standardization.
Sixtieth Report. WHO Technical Report Series No. 977, Annex 3.
Recommendations to assure the quality, safety and efficacy of pneumococcal
conjugate vaccines. Replacement of WHO Technical Report Series, No. 927,
Annex 2; 2013. <http://www.who.int/biologicals/expert_committee/TRS_977_
60th_report.pdf> [accessed 23 June 2018].
[12] Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, et al.
Estimating the protective concentration of anti-pneumococcal capsular
polysaccharide antibodies. Vaccine 2007;25:3816–26. https://doi.org/
10.1016/j.vaccine.2007.01.119.
[13] Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between
pneumococcal polysaccharide enzyme-linked immunosorbent assays with
and without 22F inhibition at low antibody concentrations in pediatric sera.
Clin Vaccine Immunol 2006;13:356–60. https://doi.org/10.1128/cvi.13.3.356-
360.2006.
[14] Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation
of pneumococcal polysaccharide immunoassays using a 22F adsorption step
with serum samples from infants vaccinated with conjugate vaccines. Clin
Vaccine Immunol 2010;17:134–42. https://doi.org/10.1128/cvi.00289-09.
[15] Biagini RE, Schlottmann SA, Sammons DL, Smith JP, Snawder JC, Striley CA,
et al. Method for simultaneous measurement of antibodies to 23
pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol
2003;10:744–50.
[16] Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development
and validation of a nonaplex assay for the simultaneous quantitation of
antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods
2005;296:135–47. https://doi.org/10.1016/j.jim.2004.11.006.[17] Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, et al.
Optimization and validation of a multiplex, electrochemiluminescence-based
detection assay for the quantitation of immunoglobulin G serotype-specific
antipneumococcal antibodies in human serum. Clin Vaccine Immunol
2009;16:387–96. https://doi.org/10.1128/cvi.00415-08.
[18] Pickering JW, Hoopes JD, Groll MC, Romero HK, Wall D, Sant H, et al. A 22-plex
chemiluminescent microarray for pneumococcal antibodies. Am J Clin Pathol
2007;128:23–31. https://doi.org/10.1309/781k5w6qh7jh2tma.
[19] Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, et al. A
multiplexed fluorescent microsphere immunoassay for antibodies to
pneumococcal capsular polysaccharides. Am J Clin Pathol 2002;117:589–96.
https://doi.org/10.1309/4keh-agy7-ut5h-41xj.
[20] Schlottmann SA, Jain N, Chirmule N, Esser MT. A novel chemistry for
conjugating pneumococcal polysaccharides to Luminex microspheres. J
Immunol Methods 2006;309:75–85. https://doi.org/10.1016/j.
jim.2005.11.019.
[21] Deaver DR. A new non-isotopic detection system for immunoassays. Nature
1995;377:758–60. https://doi.org/10.1038/377758a0.
[22] Meso Scale Discovery. MSD technology platform; 2013. <https://www.
mesoscale.com/~/media/files/brochures/techbrochure.pdf> [accessed 13
August 2018].
[23] International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH). Validation of Analytical
Procedures: Text and Methodology Q2(R1); 2005. <https://www.ich.
org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/
Step4/Q2_R1__Guideline.pdf> [accessed 23 June 2018].
[24] U.S. Department of Health and Human Services Food and Drug Administration
Center for Drug Evaluation and Research (CDER). Bioanalytical Method
Validation - Guidance for Industry (Draft); 2013.
[25] Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, et al.
Establishment of a new human pneumococcal standard reference serum,
007sp. Clin Vaccine Immunol 2011;18:1728–36. https://doi.org/10.1128/
cvi.05252-11.
[26] World Health Organization Expert Committee on Biological Standardization.
Sixty-second Report. WHO Technical Report Series No. 979, section 4.1.2: First
WHO International Standard for anti pneumococcal antibodies in serum.;
2013. <http://www.who.int/biologicals/expert_committee/TRS_979_62nd_
report.pdf> [accessed 7 August 2018].
[27] World Health Organization. Training manual for Enzyme linked
immunosorbent assay for the quantitation of Streptococcus pneumoniae
serotype specific IgG (Pn PS ELISA) (007sp Version), <http://www.vaccine.uab.
edu/uploads/mdocs/ELISAProtocol(007sp).pdf>.
[28] Linnet K. Evaluation of regression procedures for methods comparison studies.
Clin Chem 1993;39:424–32.
[29] Bacterial Respiratory Pathogen Reference Laboratory at the University of
Alabama at Birmingham. Pneumococcal ELISA Calibration Sera Panel B (for use
with 007sp); 2012. <http://www.vaccine.uab.edu/uploads/mdocs/
007spCalibrationPanel.pdf> [accessed 16 August 2018].
[30] Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al.
Enzyme-linked immunosorbent assay for quantitation of human antibodies to
pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003;10:514–9.
[31] Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus
influenzae PD conjugate vaccine: synflorix. Expert Rev Vaccines
2009;8:1479–500. https://doi.org/10.1586/erv.09.113.
[32] Nolan K, Zhang Y, Antonello J, Howlett A, Bonhomme C, Greway R, et al.
Validation of a re-optimized electrochemiluminescence-based assay for the
quantitation of IgG serotype-specific anti-pneumococcal antibodies in human
serum and bridging to the WHO reference ELISA. 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD 2018),
Melbourne, Australia, 2018.
[33] Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al.
Serotype-specific effectiveness and correlates of protection for the 13-valent
pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet
Infect Dis 2014;14:839–46. https://doi.org/10.1016/s1473-3099(14)70822-9.
